Gilead to launch Phase III once-yearly HIV PrEP trial

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...
Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...